Preleukemia
The American Journal of Medicine, ISSN: 0002-9343, Vol: 55, Issue: 1, Page: 38-48
1973
- 198Citations
- 13Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations198
- Citation Indexes198
- 198
- CrossRef176
- Captures13
- Readers13
- 13
Article Description
The literature dealing with preleukemia has been reviewed and the data compared with the clinical findings in 34 patients in whom an ill defined hematologic syndrome antedated the development of acute leukemia. These data indicate that the clinical and laboratory manifestations of the early phases of leukemia are less heterogeneous than has been generally assumed. Symptoms and physical findings lack specificity. Cytopenias dominate the early phase of this myeloproliferative syndrome. Anisocytosis and poikilocytosis with oval macrocytes are especially prominent and often suggest vitamin B 12 or folate deficiency. Other noteworthy findings in the peripheral blood include monocytosis, nucleated red cells, immature granulocytes and/or monocytes, a Pelger-Huët-like anomaly and large bizarre platelets. Bone marrow is typically normo- or hypercellular with mild maturation defects in the erythrocytic or granulocytic compartments, qualitative changes in erythrocytic precursors, monocytosis or monocytoid features of granulocytic precursors, and abundant atypical megakaryocytes. Although the bone marrow is abnormal, the changes are minimal to modest, and clear-cut findings of leukemia are lacking. Because these deviations from normal are subtle, diagnostic equivocation ensues. After a variable period of time (usually within 3 to 24 months), this myeloproliferative disorder evolves into overt leukemia (most often involving two or more marrow cell lines) and terminates with an acute leukemia characterized by an over-abundance of blast cells with morphologic features of myeloblasts and/or monoblasts.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/0002934373901484; http://dx.doi.org/10.1016/0002-9343(73)90148-4; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0015827903&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/4515079; https://linkinghub.elsevier.com/retrieve/pii/0002934373901484; http://dx.doi.org/10.1016/0002-9343%2873%2990148-4; https://dx.doi.org/10.1016/0002-9343%2873%2990148-4
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know